Literature DB >> 30546897

Evaluation of prostate-specific antigen density in the diagnosis of prostate cancer combined with magnetic resonance imaging before biopsy in men aged 70 years and older with elevated PSA.

Yoshinori Yanai1, Takeo Kosaka1, Hiroshi Hongo1, Kazuhiro Matsumoto1, Toshiaki Shinojima1, Eiji Kikuchi1, Akira Miyajima1, Ryuichi Mizuno1, Shuji Mikami2, Masahiro Jinzaki3, Mototsugu Oya1.   

Abstract

There is an increasing proportion of individuals aged 70 years and older, as well as an increasing life expectancy worldwide. The present study may guide the management of older patients with elevated prostate specific antigen (PSA). The medical records of 241 older men aged >70 years who underwent multiparametric magnetic resonance imaging (mpMRI) before prostate biopsy (PBx) at our institution were reviewed retrospectively. Multiple variables were evaluated as predictors for the diagnosis of prostate cancer (PCa). The variables included serum PSA level, digital rectal examination, size of region of interest on mpMRI, prostate volume and PSA density. PCa was positive in 162 (67.2%). Prostate volume and PSA density were significant PCa predictors (P<0.001). In patients aged 70-75 and >75 years, PSA density was significantly higher in patients with PCa (0.21 ng/ml/cc, P=0.014 and 0.24 ng/ml/cc, P<0.001, respectively). Similarly, PSA density was significant higher in patients with significant PCa (0.24 ng/ml/cc, P=0.004 and 0.29 ng/ml/cc, P<0.001, respectively). The cut-off value of PSA density was calculated using receiver operating characteristic curves. Area under curve of PSA density was 0.698, and the best cut-off value was 0.20 ng/ml/cc. These results indicate that the combination of PSA density with mpMRI before PBx is a helpful method and can be a decision-making model for a selection of PBx.

Entities:  

Keywords:  elderly men; magnetic resonance imaging; prostate biopsy; prostate cancer screening; prostate-specific antigen density

Year:  2018        PMID: 30546897      PMCID: PMC6256262          DOI: 10.3892/mco.2018.1725

Source DB:  PubMed          Journal:  Mol Clin Oncol        ISSN: 2049-9450


  19 in total

1.  Early detection of prostate cancer: AUA Guideline.

Authors:  H Ballentine Carter; Peter C Albertsen; Michael J Barry; Ruth Etzioni; Stephen J Freedland; Kirsten Lynn Greene; Lars Holmberg; Philip Kantoff; Badrinath R Konety; Mohammad Hassan Murad; David F Penson; Anthony L Zietman
Journal:  J Urol       Date:  2013-05-06       Impact factor: 7.450

2.  Outcomes of men with screen-detected prostate cancer eligible for active surveillance who were managed expectantly.

Authors:  Roderick C N van den Bergh; Stijn Roemeling; Monique J Roobol; Gunnar Aus; Jonas Hugosson; Antti S Rannikko; Teuvo L Tammela; Chris H Bangma; Fritz H Schröder
Journal:  Eur Urol       Date:  2008-09-17       Impact factor: 20.096

Review 3.  Cancer screening in the United States, 2015: a review of current American cancer society guidelines and current issues in cancer screening.

Authors:  Robert A Smith; Deana Manassaram-Baptiste; Durado Brooks; Mary Doroshenk; Stacey Fedewa; Debbie Saslow; Otis W Brawley; Richard Wender
Journal:  CA Cancer J Clin       Date:  2015-01-08       Impact factor: 508.702

4.  Prostate specific antigen adjusted for transition zone volume: the most powerful method for detecting prostate carcinoma.

Authors:  E Kikuchi; J Nakashima; M Ishibashi; T Ohigashi; H Asakura; M Tachibana; M Murai
Journal:  Cancer       Date:  2000-08-15       Impact factor: 6.860

5.  The Value of PSA Density in Combination with PI-RADS™ for the Accuracy of Prostate Cancer Prediction.

Authors:  Florian A Distler; Jan P Radtke; David Bonekamp; Claudia Kesch; Heinz-Peter Schlemmer; Kathrin Wieczorek; Marietta Kirchner; Sascha Pahernik; Markus Hohenfellner; Boris A Hadaschik
Journal:  J Urol       Date:  2017-03-31       Impact factor: 7.450

6.  Active surveillance program for prostate cancer: an update of the Johns Hopkins experience.

Authors:  Jeffrey J Tosoian; Bruce J Trock; Patricia Landis; Zhaoyong Feng; Jonathan I Epstein; Alan W Partin; Patrick C Walsh; H Ballentine Carter
Journal:  J Clin Oncol       Date:  2011-04-04       Impact factor: 44.544

7.  Three-Tesla magnetic resonance-guided prostate biopsy in men with increased prostate-specific antigen and repeated, negative, random, systematic, transrectal ultrasound biopsies: detection of clinically significant prostate cancers.

Authors:  Caroline M A Hoeks; Martijn G Schouten; Joyce G R Bomers; Stefan P Hoogendoorn; Christina A Hulsbergen-van de Kaa; Thomas Hambrock; Henk Vergunst; J P Michiel Sedelaar; Jurgen J Fütterer; Jelle O Barentsz
Journal:  Eur Urol       Date:  2012-02-01       Impact factor: 20.096

8.  Effect of age, tumor risk, and comorbidity on competing risks for survival in a U.S. population-based cohort of men with prostate cancer.

Authors:  Timothy J Daskivich; Kang-Hsien Fan; Tatsuki Koyama; Peter C Albertsen; Michael Goodman; Ann S Hamilton; Richard M Hoffman; Janet L Stanford; Antoinette M Stroup; Mark S Litwin; David F Penson
Journal:  Ann Intern Med       Date:  2013-05-21       Impact factor: 25.391

9.  Prognostic value of preoperative multiparametric magnetic resonance imaging (MRI) for predicting biochemical recurrence after radical prostatectomy.

Authors:  Seiya Hattori; Takeo Kosaka; Ryuichi Mizuno; Kent Kanao; Akira Miyajima; Yota Yasumizu; Satoshi Yazawa; Hirohiko Nagata; Eiji Kikuchi; Shuji Mikami; Masahiro Jinzaki; Ken Nakagawa; Akihiro Tanimoto; Mototsugu Oya
Journal:  BJU Int       Date:  2013-08-13       Impact factor: 5.588

10.  ESUR prostate MR guidelines 2012.

Authors:  Jelle O Barentsz; Jonathan Richenberg; Richard Clements; Peter Choyke; Sadhna Verma; Geert Villeirs; Olivier Rouviere; Vibeke Logager; Jurgen J Fütterer
Journal:  Eur Radiol       Date:  2012-02-10       Impact factor: 5.315

View more
  1 in total

1.  Optimal PSA Threshold for Obtaining MRI-Fusion Biopsy in Biopsy-Naïve Patients.

Authors:  Luke L Wang; Brandon L Henslee; Peter B Sam; Chad A LaGrange; Shawna L Boyle
Journal:  Prostate Cancer       Date:  2021-07-01
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.